Literature DB >> 10884023

Melatonin limits transcriptional impact of phosphoCREB in the mouse SCN via the Mel1a receptor.

C von Gall1, D R Weaver, M Kock, H W Korf, J H Stehle.   

Abstract

In the mouse, activity phase-shifts of the endogenous clock in the suprachiasmatic nucleus (SCN) are associated with phosphorylation of the transcription factor Ca2+/cAMP responsive element binding protein (CREB). CREB phosphorylation is induced by the retino-hypothalamic transmitter pituitary adenylate cyclase-activating polypeptide (PACAP). As detected by immunohistochemistry in SCN slices from wild-type mice, melatonin completely blocked PACAP-stimulated CREB phosphorylation at low concentrations (1 nM). In Mel1a melatonin receptor-deficient mice, the PACAP-induced CREB phosphorylation was inhibited only at melatonin concentrations of 100 nM. This inhibition was, however, blunted by blocking the Mel1b melatonin receptor. Thus, melatonin modulates PACAP-mediated retinal stimuli for clock entrainment primarily via the Mel1a melatonin receptor through molecular interaction within the cAMP-signalling pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884023     DOI: 10.1097/00001756-200006260-00002

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  12 in total

1.  Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice.

Authors:  Oliver Rawashdeh; Randall L Hudson; Iwona Stepien; Margarita L Dubocovich
Journal:  Chronobiol Int       Date:  2011-02       Impact factor: 2.877

2.  Dopamine receptor-mediated regulation of neuronal "clock" gene expression.

Authors:  M Imbesi; S Yildiz; A Dirim Arslan; R Sharma; H Manev; T Uz
Journal:  Neuroscience       Date:  2008-11-05       Impact factor: 3.590

Review 3.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

Review 4.  Functional MT1 and MT2 melatonin receptors in mammals.

Authors:  Margarita L Dubocovich; Magdalena Markowska
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

5.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 6.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

7.  Targeted disruption of the mouse Mel(1b) melatonin receptor.

Authors:  Xiaowei Jin; Charlotte von Gall; Rick L Pieschl; Valentin K Gribkoff; Jorg H Stehle; Steven M Reppert; David R Weaver
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

8.  Melatonin.

Authors:  Paul Pévet
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

Review 9.  Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder: A Systematic Review of Randomized Clinical Trials.

Authors:  Tarun Parvataneni; Sushma Srinivas; Kaushal Shah; Rikinkumar S Patel
Journal:  Cureus       Date:  2020-05-28

10.  Expression of Melatonin and Dopamine D3 Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension.

Authors:  Irene Reyes-Resina; Hanan Awad Alkozi; Anna Del Ser-Badia; Juan Sánchez-Naves; Jaume Lillo; Jasmina Jiménez; Jesús Pintor; Gemma Navarro; Rafael Franco
Journal:  Cells       Date:  2020-01-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.